AXL and cancer: Although AXL is not considered a major oncogenic driver, its overexpression has been found to be correlated with a wide array of cancer-related events, including resistance to certain targeted agents and chemotherapy, tumor angiogenesis and metastasis, suppression of anti-tumor immune response, and EMT (17).